197 related articles for article (PubMed ID: 10329429)
1. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.
Ohtomo T; Sugamata Y; Ozaki Y; Ono K; Yoshimura Y; Kawai S; Koishihara Y; Ozaki S; Kosaka M; Hirano T; Tsuchiya M
Biochem Biophys Res Commun; 1999 May; 258(3):583-91. PubMed ID: 10329429
[TBL] [Abstract][Full Text] [Related]
2. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
3. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
[TBL] [Abstract][Full Text] [Related]
5. Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.
Kawai S; Koishihara Y; Iida S; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Leuk Res; 2006 Aug; 30(8):949-56. PubMed ID: 16473407
[TBL] [Abstract][Full Text] [Related]
6. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
7. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity.
Ono K; Ohtomo T; Yoshida K; Yoshimura Y; Kawai S; Koishihara Y; Ozaki S; Kosaka M; Tsuchiya M
Mol Immunol; 1999 Apr; 36(6):387-95. PubMed ID: 10444002
[TBL] [Abstract][Full Text] [Related]
8. Complementary DNA cloning and characterization of RANDAM-2, a type I membrane molecule specifically expressed on glutamatergic neuronal cells in the mouse cerebrum.
Kotani M; Tajima Y; Osanai T; Irie A; Iwatsuki K; Kanai-Azuma M; Imada M; Kato H; Shitara H; Kubo H; Sakuraba H
J Neurosci Res; 2003 Sep; 73(5):603-13. PubMed ID: 12929128
[TBL] [Abstract][Full Text] [Related]
9. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.
Ozaki S; Kosaka M; Wakahara Y; Ozaki Y; Tsuchiya M; Koishihara Y; Goto T; Matsumoto T
Blood; 1999 Jun; 93(11):3922-30. PubMed ID: 10339501
[TBL] [Abstract][Full Text] [Related]
10. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26.
Zannettino AC; Harrison K; Joyner CJ; Triffitt JT; Simmons PJ
J Cell Biochem; 2003 May; 89(1):56-66. PubMed ID: 12682908
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning, expression, and chromosomal localization of a human tubulointerstitial nephritis antigen.
Ikeda M; Takemura T; Hino S; Yoshioka K
Biochem Biophys Res Commun; 2000 Feb; 268(1):225-30. PubMed ID: 10652240
[TBL] [Abstract][Full Text] [Related]
13. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.
Wang W; Nishioka Y; Ozaki S; Jalili A; Abe S; Kakiuchi S; Kishuku M; Minakuchi K; Matsumoto T; Sone S
Cancer Immunol Immunother; 2009 Jun; 58(6):967-76. PubMed ID: 18979097
[TBL] [Abstract][Full Text] [Related]
14. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
[TBL] [Abstract][Full Text] [Related]
15. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.
Ozaki S; Kosaka M; Wakatsuki S; Abe M; Koishihara Y; Matsumoto T
Blood; 1997 Oct; 90(8):3179-86. PubMed ID: 9376601
[TBL] [Abstract][Full Text] [Related]
17. Enforced expression of superoxide dismutase 2/manganese superoxide dismutase disrupts autocrine interleukin-6 stimulation in human multiple myeloma cells and enhances dexamethasone-induced apoptosis.
Hodge DR; Xiao W; Peng B; Cherry JC; Munroe DJ; Farrar WL
Cancer Res; 2005 Jul; 65(14):6255-63. PubMed ID: 16024627
[TBL] [Abstract][Full Text] [Related]
18. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
[TBL] [Abstract][Full Text] [Related]
19. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
20. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
